the Study of some pro- inflammatory and Anti –inflammatory interleukins in diabetic patients
DOI:
https://doi.org/10.24237/ASJ.02.04.888CKeywords:
Diabetic mellitus (DM),, Immunity, , IL-38 and IL-39Abstract
Objective; The objective of present research is evaluation roles of IL-38 and IL-39 indicators in pathophysiology of diabetic mellitus type II.
Methods; The conducted investigation was occurred inside Bagdad capital during time period 1/8 to 30/11 month of 2023 year. Forty five (45) blood samples had from patients suffering from type II diabetes that attending outpatients clinics after screening them by specialist physician . Additionally, 45 blood samples were collected from individuals without disease and considered them as control group. All markers were quantified in all participants by utilize enzyme linked immunesorbent assay (ELISA) with kits provided from Bio-Sources International (Camarillo, CA, USA). Results of current investigation were calculated by SPSS v. 21.0 and Prism v.6 statistical software programs.
Results; Findings of current investigation showed no significant differences (p>0.05) between study groups according to gender and age groups. Significant raise (p<0.05) levels of IL-38 and IL-39 in type II diabetic patients than healthy. ROC curve outcomes present the IL-38 showed highest sensitivity and specificity (96% and 95%) compared to IL-39 (sensitivity (80%) and specificity (75%)) at cut off (>251.21 and > 182.29) respectively in predicting individuals with diabetes mellitus type II with significant variation (p<0.05). Our outcomes showed no significant differences (p>0.05) between levels of IL-38 and IL-39 and gender as well as to age groups in patients with diabetes. Finally, pearson correlation coefficient results reveals no significant correlation (P>0.05) between IL-38 and IL-39 in diabetes patients .
Conclusions; We concluded there is no effect of gender and age on diabetes mellitus. Increased levels of pro and anti-inflammatory interleukins (IL-39 and IL-38) in patients due to inflammation. Anti-inflammatory interleukin (IL-38) increased due to effect of pro- inflammatory interleukin (IL-39) to reducing the intensity of inflammatory reactions and preserving physiological equilibrium in essential organs. IL-38 is highly preferred in predicting diabetic patients than IL-39 due to it has highest sensitivity and specificity. There is no effect of gender and age on levels of these interleukins in DM patients. Finally, it is founded there is no significant correlation between IL-38 and IL-39 in those patients.
References
• Abdelkawy, M., Shaker, O. G., & Tarrad, N. A. F. (2024). IL-39 and IL-35 gingival crevicular fluid levels in diabetic patients with generalized periodontitis. Clinical Oral Investigations, 28(2), 1-11.
• Abdul Basith Khan, M., Hashim, M. J., King, J. K., Govender, R. D., Mustafa, H., & Al Kaabi, J. (2020). Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. Journal of epidemiology and global health, 10(1), 107-111.
• Ali, J., Haider, S. M. S., Ali, S. M., Haider, T., Anwar, A., & Hashmi, A. A. (2023). Overall clinical features of type 2 diabetes mellitus with respect to gender. Cureus, 15(3).
• Aliyeva, A. M., Baykova, I. E., Pinchuk, T. V., Kotikova, I. A., & Nikitin, I. G. (2023). Interleukin-38 and cardiovascular pathology: literature review. CardioSomatics.
• Alrouji, M., Al‐kuraishy, H. M., Al‐Gareeb, A. I., Alexiou, A., Papadakis, M., Jabir, M. S., ... & Batiha, G. E. S. (2023). NF‐κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective. Journal of Cellular and Molecular Medicine, 27(13), 1775-1789.
• Bastian, D., Sui, X., Nguyen, H. D., Wu, Y., Schutt, S., Tian, L., ... & Yu, X. Z. (2021). Interleukin-23 receptor signaling by interleukin-39 potentiates T cell pathogenicity in acute graft-versus-host disease. American Journal of Transplantation, 21(11), 3538-3549.
• Bhatt, P. P., & Sheth, M. S. (2024). Comparison of fatigue and functional status in elderly type 2 diabetes patients versus age and gender matched individuals. Aging Medicine.
• Chakraborty, R., Parveen, R., Varshney, P., Kapur, P., Khatoon, S., Saha, N., & Agarwal, N. B. (2021). Elevated urinary IL-36α and IL-18 levels are associated with diabetic nephropathy in patients with type 2 diabetes mellitus. Minerva Endocrinology, 46(2), 226-232.
• Dai, S., Shu, D., Meng, F., Chen, Y., Wang, J., Liu, X., ... & Chen, F. (2023). Higher risk of sarcopenia in older adults with type 2 diabetes: NHANES 1999–2018. Obesity facts, 16(3), 237-248.
• Ecoeur, F., Weiss, J., Schleeger, S., & Guntermann, C. (2020). Lack of evidence for expression and function of IL-39 in human immune cells. Plos one, 15(12), e0242329.
• ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., ... & Gabbay, R. A. (2023). Summary of revisions: Standards of Care in Diabetes—2023. Diabetes Care, 46(Supplement_1), S5-S9.
• Fruehbeck, G., Gomez-Ambrosi, J., Ramirez, B., Mentxaka, A., Rodriguez, A., Becerril, S., ... & Catalan, V. (2022). Increased levels of interleukin-36 in obesity and type 2 diabetes fuel adipose tissue inflammation by inducing its own expression and release by adipocytes and macrophages. Frontiers in Immunology, 13, 832185.
• Goldney, J., Sargeant, J. A., & Davies, M. J. (2023). Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. Diabetologia, 66(10), 1832-1845.
• Guo, M., Gao, J., Jiang, L., & Dai, Y. (2023). Astragalus Polysaccharide Ameliorates Renal Inflammatory Responses in a Diabetic Nephropathy by Suppressing the TLR4/NF-κB Pathway. Drug Design, Development and Therapy, 2107-2118.
• Huang, G., Li, M., Tian, X., Jin, Q., Mao, Y., & Li, Y. (2022). The emerging roles of IL-36, IL-37, and IL-38 in diabetes mellitus and its complications. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders), 22(10), 997-1008.
• Kautzky-Willer, A., Leutner, M., & Harreiter, J. (2023). Sex differences in type 2 diabetes. Diabetologia, 66(6), 986-1002.
• Li, D., Zhong, J., Zhang, Q., & Zhang, J. (2023). Effects of anti-inflammatory therapies on glycemic control in type 2 diabetes mellitus. Frontiers in Immunology, 14, 1125116.
• Liu, Y., Chen, T., Zhou, F., Mu, D., & Liu, S. (2020). Interleukin-38 increases the insulin sensitivity in children with the type 2 diabetes. International Immunopharmacology, 82, 106264.
• Lu, Z., Xu, K., Wang, X., Li, Y., & Li, M. (2020). Interleukin 39: a new member of interleukin 12 family. Central European Journal of Immunology, 45(2), 214-217.
• Luo, Y., Liu, F., Liu, H., Chen, H., Cheng, W., Dong, S., & Xiong, W. (2017). Elevated serum IL-39 in patients with ST-segment elevation myocardial infarction was related with left ventricular systolic dysfunction. Biomarkers in Medicine, 11(6), 419-426.
• Matsumori, A. (2023). Nuclear factor-κB is a prime candidate for the diagnosis and control of inflammatory cardiovascular disease. European Cardiology Review, 18.
• Nassurat, S. W., Salman, I. N., & Ad’hiah, A. H. (2024). Association of interleukin-36α and interleukin-38 with type 2 diabetes mellitus and diabetic neuropathy. The Egyptian Journal of Internal Medicine, 36(1), 24.
• Nirenjen, S., Narayanan, J., Tamilanban, T., Subramaniyan, V., Chitra, V., Fuloria, N. K., ... & Selvaraj, S. (2023). Exploring the contribution of pro-inflammatory cytokines to impaired wound healing in diabetes. Frontiers in immunology, 14, 1216321.
• Nussrat, S. W., & Ad'hiah, A. H. (2023). Interleukin‐39 is a novel cytokine associated with type 2 diabetes mellitus and positively correlated with body mass index. Endocrinology, diabetes & metabolism, 6(3), e409.
• Vasanthakumar, A., & Kallies, A. (2019). Interleukin (Il)-33 and the il-1 family of cytokines—regulators of inflammation and tissue homeostasis. Cold Spring Harbor perspectives in biology, 11(3), a028506.
• Velikova, T. V., Kabakchieva, P. P., Assyov, Y. S., & Georgiev, T. А. (2021). Targeting inflammatory cytokines to improve type 2 diabetes control. BioMed research international, 2021.
• Wang, X. R., Xiao, J. P., & Wang, D. G. (2021). Elevated levels of serum IL 36α in patients with systemic lupus erythematosus. Biomedical reports, 15(3), 1-7.
• Wang, X., Zhang, Y., Wang, Z., Liu, X., Zhu, G., Han, G., ... & Wang, R. (2018). Anti IL 39 (IL 23p19/Ebi3) polyclonal antibodies ameliorate autoimmune symptoms in lupus like mice. Molecular Medicine Reports, 17(1), 1660-1666.
• Weng, L., Huang, G., Gong, L., Xu, J., Mao, Y., Li, Y., & Li, M. (2022). Low levels of serum IL‐39 are associated with autoimmune thyroid disease. Journal of clinical laboratory analysis, 36(4), e24284.
• Zhao, T., Yu, M., Li, M., & Li, Y. (2022). Serum IL-38 levels in patients with type 2 diabetes mellitus. Endokrynologia Polska, 73(6), 988-989.
• Zheng, H., Sun, W., Zhang, Q., Zhang, Y., Ji, L., Liu, X., ... & Zhang, S. (2021). Proinflammatory cytokines predict the incidence of diabetic peripheral neuropathy over 5 years in Chinese type 2 diabetes patients: a prospective cohort study. EClinicalMedicine, 31.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 CC BY 4.0
This work is licensed under a Creative Commons Attribution 4.0 International License.
